News & Updates
Showing Oncology articles
Showing
Show Multimedia Only

ARTEMIS-008: Risvutatug rezetecan shows promise as new standard of care for relapsed SCLC
21 Oct 2026
byStephen Padilla
Treatment with the B7-H3-directed antibody-drug conjugate risvutatug rezetecan (Ris-Rez) results in significant improvements in overall survival (OS) compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) who had progressed after receiving platinum-based chemotherapy, as shown by the results of the phase III ARTEMIS-008 trial.
21 Oct 2026

No OS benefit to adding LCT after NIVO-IPI in metastatic NSCLC
12 Oct 2026
byElvira Manzano
Adding local consolidative therapy (LCT) after induction with nivolumab and ipilimumab does not improve survival in immunotherapy-naïve patients with metastatic non–small cell lung cancer (NSCLC), as shown in the phase III LONESTAR trial presented at WCLC 2026.
12 Oct 2026






